- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Uterine Cancer, Mesotheliomas, Gastrointestinal Cancers, Cervical Cancer
- Interventions
- HIPEC: MMC 30mg @ T0, 10mg @ T45min, HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0, HIPEC: CDDP 75 mg/m2 @T0, HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0
- Device
- Lead sponsor
- Bay Area Gynecology Oncology
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2022
- U.S. locations
- 1
- States / cities
- Los Gatos, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2545–2568
of 5,570
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetic Macular Edema
- Interventions
- iCo-007 350 mcg, iCo-007 700 mcg, iCo-007 350 mcg and Laser, Ranibizumab and iCo-007 350 mcg
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Hypoactive Sexual Desire Disorder
- Interventions
- Placebo, Testosterone, Buspirone hydrochloride
- Drug
- Lead sponsor
- Emotional Brain NY Inc.
- Industry
- Eligibility
- 21 Years to 70 Years · Female only
- Enrollment
- 207 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 12
- States / cities
- San Diego, California • Bradenton, Florida • North Miami, Florida + 9 more
- Conditions
- Advanced Solid Tumor
- Interventions
- NB004 tablets
- Drug
- Lead sponsor
- Ningbo Newbay Technology Development Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- New Orleans, Louisiana • Houston, Texas
- Conditions
- Hepatitis C, Hiv, Coinfection, HIV, Substance Use Disorders
- Interventions
- Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
- Drug
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Peripheral Arterial Disease, Peripheral Vascular Diseases, Catheterization, Peripheral
- Interventions
- NVS Therapy
- Combination Product
- Lead sponsor
- Alucent Biomedical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Columbus, Ohio • Wynnewood, Pennsylvania • Kingsport, Tennessee
- Conditions
- Obesity
- Interventions
- Naltrexone-Bupropion Combination
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer, Pancreatic Cancer
- Interventions
- SY-5609, Fulvestrant, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- Syros Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Los Angeles, California • Orlando, Florida + 11 more
- Conditions
- HIV-1-infection
- Interventions
- Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir, Failing ARV Regimen, Optimized Background Regimen (OBR)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 35
- States / cities
- Los Angeles, California • Palm Springs, California • Sacramento, California + 28 more
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Abacavir sulfate, Amprenavir, Lamivudine
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 15 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 2
- States / cities
- New York, New York • Providence, Rhode Island
- Conditions
- HIV Infections, Sinusitis
- Interventions
- Pseudoephedrine hydrochloride, Guaifenesin, Cefuroxime axetil, Beclomethasone dipropionate
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1993
- U.S. locations
- 10
- States / cities
- San Diego, California • San Francisco, California • The Bronx, New York + 1 more
- Conditions
- Asthma
- Interventions
- pMDI budesonide/formotrol 160/4.5 is in group 1, Symbicort 160/4.5 plus Aerochamber Plus included in group 2
- Drug · Device
- Lead sponsor
- Western Sky Medical Research
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- El Paso, Texas
- Conditions
- HIV Infections
- Interventions
- Kaletra + Isentress, Atripla
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 6
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 3 more
- Conditions
- Breast Cancer Metastatic, Breast Cancer
- Interventions
- Olaparib, Vorinostat
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Muscle-Invasive Bladder Carcinoma, Bladder Cancer, Urothelial Carcinoma
- Interventions
- Gemzar, Cisplatin, Adrucil, Mitomycin, Radical Cystectomy
- Drug · Procedure
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Melanoma, Melanoma, BRAF-mutated Metastatic Melanoma, V600EBRAF-mutated Metastatic Melanoma
- Interventions
- Vemurafenib + Cobimetinib, Decitabine
- Drug
- Lead sponsor
- Mohammed M Milhem
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Glioblastoma, Anaplastic Astrocytoma
- Interventions
- ADV/HSV-tk (gene therapy)
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Adrenal Cortical Carcinoma
- Interventions
- doxorubicin, vincristine, and etoposide with mitotane
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Myelodysplastic Syndrome, MDS
- Interventions
- pracinostat, Azacitidine, Decitabine
- Drug
- Lead sponsor
- Helsinn Healthcare SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Duarte, California • Los Angeles, California + 17 more
- Conditions
- HIV
- Interventions
- Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir
- Drug
- Lead sponsor
- Kenneth H. Mayer, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus
- Interventions
- Alogliptin and pioglitazone, Pioglitazone
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 61 more
- Conditions
- Cystic Fibrosis
- Interventions
- LUM/IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 34 more
- Conditions
- Breast Cancer
- Interventions
- Nivolumab, Cabozantinib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Melanoma
- Interventions
- Entinostat, Pembrolizumab
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina